Fight Aging! Newsletter, January 29th 2024
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter,
please visit:
https://www.fightaging.org/newsletter/
Longevity Industry Consulting Services
Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - January 28, 2024 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Reviewing the Potential for Klotho as a Basis for Therapy
Klotho is one of the few robustly longevity-associated genes discovered over the past few decades. Increased levels of the circulating α-klotho protein slows aging in mice and is associated with better late life health in humans. Additionally, more of this α-klotho appears to slow cognitive aging and also boost cognitive function in younger animals. While klotho is thought to be primarily active in the kidneys, and thus indicates the importance of declining kidney function in degenerative aging, researchers are discovering potentially relevant interactions in the brain. It remains an open question as to how exactly kloth...
Source: Fight Aging! - January 24, 2024 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
LEV Foundation on Senolytics as One Part of a Combination Rejuvenation Therapy
The primary focus of the Longevity Escape Velocity (LEV) Foundation is to demonstrate that therapies based on the repair of forms of underlying molecular damage that cause aging can be combined to produce greater rejuvenation. Research of recent years has demonstrated quite comprehensively that the alternative strategy for treating aging, to manipulate metabolism into a state in which aging occurs modestly more slowly, has so far produced therapies that largely cannot be combined. The combination of any two or more metabolic alterations, induced by supplements or other small molecules, that individually modestly slow aging...
Source: Fight Aging! - January 22, 2024 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Health IT – 2024 Health IT Predictions
As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. In fact, we got so many that we had to narrow them down to just the best and most interesting. Check out our community’s predictions below and be sure to add your own thoughts and/or places you disagree with these predictions in the comments and on social media.
All of this year’s 2024 health IT predictions (updated as they’re shared):
John and ...
Source: EMR and HIPAA - January 18, 2024 Category: Information Technology Authors: John Lynn Tags: Ambulatory C-Suite Leadership Health IT Company Healthcare IT Hospital - Health System LTPAC 2024 Health IT Predictions Aasim Saeed Amenities Health Andrew Harding Ankit Gupta Anthony Hare Ash Wellness Availity Bicycle Health Source Type: blogs
Fight Aging! Newsletter, January 1st 2024
Discussion of What is Need to Speed the Pace at which Drugs to Treat Aging Arrive in the Clinic
Cellular Senescence in the Aging Brain, a Contributing Cause of Cognitive Decline
Reviewing What is Known of the Mechanisms of Taurine Supplementation Relevant to Aging and Metabolism
Blunt Thoughts on Calculating the Revealed Value of Human Life
A Look Back at 2023: Progress Towards the Treatment of Aging as a Medical Condition
Towards Adjustment of the Gut Microbiome to Slow Aging
Gene Therapy Enhances Object Recognition Memory in Young and Old Mice
Benefits of Sem...
Source: Fight Aging! - December 31, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
A Look Back at 2023: Progress Towards the Treatment of Aging as a Medical Condition
The market has been in the doldrums and it has been a tough year for fundraising, both for non-profits and biotech startups. The conferences have exhibited more of an academic focus as companies tightened belts and postponed investment rounds, while investors stayed home. Not that this halts the flow of hype for some projects, and nor has it slowed media commentary on the longevity industry as it presently stands. A few of the articles in that commmentary are even interesting to read! The field has grown and is more mature now than has ever been the case. Biotech of all forms is a challenging field with a high failure rate...
Source: Fight Aging! - December 29, 2023 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs
Angiotensin 1-7 Improves Skeletal Muscle Regeneration
Researchers here demonstrate that administration of angiotensin (1-7) protein to injured muscles in mice provokes improved regeneration of muscle tissue. Protein therapies are an expensive proposition at this point in time, so the usual approach for research of this nature is to look for a small molecule that upregulates expression of the desired protein. That said, gene therapies are looking ever more promising for any use case in which the objective is to increase levels of a circulating protein. Only a small number of cells, such as subcutaneous fat cells, need to be transfected via an injected therapy in order to produ...
Source: Fight Aging! - December 28, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Gene Therapy Enhances Object Recognition Memory in Young and Old Mice
In this study, we demonstrated that the same treatment with RGS14414 in visual area V2, which is relatively unaffected in neurodegenerative diseases such as Alzheimer's disease, produced long-lasting enhancement of ORM in young animals and prevent ORM deficits in rodent models of aging and Alzheimer's disease. Furthermore, we found that the prevention of memory deficits was mediated through the upregulation of neuronal arborization and spine density, as well as an increase in brain-derived neurotrophic factor (BDNF). A knockdown of BDNF gene in RGS14414-treated aging rats and Alzheimer's disease model mice caused complete ...
Source: Fight Aging! - December 25, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, December 25th 2023
This study generates a comprehensive single-cell transcriptomic atlas of human atherosclerosis including 118,578 high-quality cells from atherosclerotic coronary and carotid arteries. By performing systematic benchmarking of integration methods, we mitigated data overcorrection while separating major cell lineages. Notably, we define cell subtypes that have not been previously identified from individual human atherosclerosis scRNA-seq studies.
Besides characterizing granular cell-type diversity and communication, we leverage this atlas to provide insights into smooth muscle cell (SMC) modulation. We integrate genome...
Source: Fight Aging! - December 24, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Profiling the Development of Gene Therapies at Rejuvenate Bio
Here find a high-level look at the work of Rejuvenate Bio, a gene therapy company aiming to manipulating aging metabolism into a better shape. They have chosen to focus on the strategy of altering tissues to generate signal molecules known to be influential in the progression of aging. This is perhaps the easiest way forward for any gene therapy platform. Gene therapies are clearly the future, but at present it is somewhere between hard, expensive, and impossible to specifically target a gene therapy to most organs or cell types or tissues. If one can use one of the few established approaches, such as delivery of a gene th...
Source: Fight Aging! - December 21, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, December 18th 2023
In conclusion, given the relative safety and the favourable effects of aspirin, its use in cancer seems justified, and ethical implications of this imply that cancer patients should be informed of the present evidence and encouraged to raise the topic with their healthcare team.
« Back to Top
Aged Transplant Organs Cause Harm to Younger Recipients
https://www.fightaging.org/archives/2023/12/aged-transplant-organs-cause-harm-to-younger-recipients/
Old tissues are dysfunctional in ways that young tissues are not. This has always been known in the context of organ transplants, but absent me...
Source: Fight Aging! - December 17, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Klotho Levels Decline with Age, But Are Unaffected by Physical Fitness at a Given Age
Klotho is a longevity-associated gene. Klotho functions within the cell, but a portion of the full protein is also released into the bloodstream. In humans, higher levels of circulating klotho correlate with lower incidence of age-related disease and mortality. In mice, interventions such as gene therapies that increase klotho levels have been shown to extend life, while reducing klotho levels shortens life. Klotho is thought to act within the kidney, where it is protective, slowing age-related decline of kidney function. Increased klotho levels produce cognitive improvement in mice and non-human primates, however, and hig...
Source: Fight Aging! - December 13, 2023 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, December 11th 2023
In this study, a single treatment at the peak of disease resulted in the ablation of senescent cells in the lung and attenuation of key fibrotic and inflammatory markers, which ultimately resolved fibrosis. Deciduous Therapeutics has used computational assisted design to synthesise a suite of proprietary therapies that could be used in the clinic to re-activate tissue-resident iNKT cells. To date, the company's lead program has shown single-dose efficacy in resolving both metabolic and fibrotic diseases along with a favorable safety profile at doses significantly higher than the efficacious dose.
« Back to ...
Source: Fight Aging! - December 10, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
The State Of CRISPR Clinical Trials And Their Future Potentials
CRISPR, short for “Clustered Regularly Interspaced Short Palindromic Repeats” – and more specifically CRISPR–Cas9 – relates to a gene-editing method that gained popularity in the past decade; and not for trivial reasons. Being the most efficient and accurate method to edit a cell’s genome, CRISPR holds potentials that range from treating conditions such as HIV to finding new drug targets.
While such potentials are real and are being actively investigated, you might be curious about more practical examples of CRISPR applications. By taking the US Clinical Trials registry as an example, we consider lis...
Source: The Medical Futurist - December 7, 2023 Category: Information Technology Authors: Pranavsingh Dhunnoo Tags: TMF CRISPR therapy clinical trials gene editing Source Type: blogs
A Longevity Industry Feature in Biopharma Dealmakers: Repair Biotechnologies, Deciduous Therapeutics, and More
In this study, a single treatment at the peak of disease resulted in the ablation of senescent cells in the lung and attenuation of key fibrotic and inflammatory markers, which ultimately resolved fibrosis. Deciduous Therapeutics has used computational assisted design to synthesise a suite of proprietary therapies that could be used in the clinic to re-activate tissue-resident iNKT cells. To date, the company's lead program has shown single-dose efficacy in resolving both metabolic and fibrotic diseases along with a favorable safety profile at doses significantly higher than the efficacious dose. (Source: Fight Aging!)
Source: Fight Aging! - December 4, 2023 Category: Research Authors: Reason Tags: Longevity Industry Source Type: blogs
